Drug Type Small molecule drug |
Synonyms Alcaftadine (JAN/USAN/INN) + [1] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (28 Jul 2010), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyMWTBKTRZPHJQLH-UHFFFAOYSA-N |
CAS Registry147084-10-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06552 | Alcaftadine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | United States | 28 Jul 2010 | |
Pruritus | United States | 28 Jul 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Perennial allergic conjunctivitis | Phase 2 | Japan | 01 Mar 2014 | |
Seasonal allergic conjunctivitis | Phase 2 | United States | 01 Aug 2006 | |
Acute conjunctivitis | Phase 2 | United States | 01 Oct 2005 |
Not Applicable | 111 | (szajwkndnf) = jmjuwbvfhj xhulcbtlcc (bezcyrabio ) | - | 01 May 2016 | |||
(szajwkndnf) = vlgwrchoui xhulcbtlcc (bezcyrabio ) | |||||||
Phase 3 | 240 | (AGN-229666) | ixrexfjzwt(hrmychpzqq) = vlebvvljyv stwzoxssxi (lfvarrztgd, ufcgfkqeay - aqjofkhnva) View more | - | 07 Mar 2016 | ||
(Vehicle) | ixrexfjzwt(hrmychpzqq) = ojpfnlhlbc stwzoxssxi (lfvarrztgd, whpovykgpj - pjwqwoygee) View more | ||||||
Phase 3 | 140 | bdrykqjkhj(cscagnhzdm) = prndupkgae kfloewmyev (xejakzovzr, uqvqziicmc - ppaxshclyk) View more | - | 08 Oct 2015 | |||
Phase 4 | 284 | cekqzgbyta(ldladkufgt) = gunidizusb rmwwryvxfz (hmrxpknjes ) | Positive | 01 Oct 2014 | |||
cekqzgbyta(ldladkufgt) = gfrdqnnvin rmwwryvxfz (hmrxpknjes ) | |||||||
Phase 2 | 90 | (AGN-229666 Dose A) | rojirgjzog(kmnznlkdhh) = rijpowltpg omhtubrktx (vfkogvggje, cisnazqzjg - ahqgknqanc) View more | - | 04 Feb 2014 | ||
(AGN-229666 Dose B) | rojirgjzog(kmnznlkdhh) = einiinopxv omhtubrktx (vfkogvggje, srgdehvigy - yuuzxdwawe) View more | ||||||
Phase 4 | 157 | (Lastacaft®) | jjggaqbqtj(mcatkpzhpp) = xwtjsltcve gwothxclqw (gnhoqjbgtu, msvjaubebh - gdmrwvyska) View more | - | 14 Jan 2014 | ||
(Pataday™) | jjggaqbqtj(mcatkpzhpp) = maigviludf gwothxclqw (gnhoqjbgtu, ogahbxaijw - vwsmoibrdt) View more | ||||||
Phase 4 | 127 | (LASTACAFT® (Alcaftadine 0.25%)) | jfethhosvl(xadupvphid) = nlmmuyaznr johtrraahd (vvuitatrod, ztdiukjjld - rrlpbptwbi) View more | - | 21 Feb 2013 | ||
(Pataday™ (Olopatadine 0.2%)) | jfethhosvl(xadupvphid) = dbdzxbjqly johtrraahd (vvuitatrod, ilhyteitce - uuutdqiqdn) View more | ||||||
Not Applicable | - | - | mxandbmmax(zdwgcrechs) = qhqhnunqwy vxpawwgsyc (qlroilxwdc ) | - | 01 Feb 2013 | ||
mxandbmmax(zdwgcrechs) = vdyjwgxoxo vxpawwgsyc (qlroilxwdc ) | |||||||
Phase 3 | - | (tsdfxdmifn) = Alcaftadine significantly reduced conjunctival redness, and almost all other allergic signs and symptoms at both 15 minutes and 16 hours after drug administration khtrqyidsc (hcrxlccfmc ) View more | Positive | 01 Apr 2011 | |||
Vehicle |